ERBB2 and breast carcinoma: Overall, in dose-dependent drug sensitivity test, DF, as a single agent, did not significantly inhibit the growth of EGFR/ERBB2-amplified gastroesophageal and breast cancer cell lines even at supra-pharmacological doses (Figure 2).